Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baricitinib - Eli Lilly and Company/Incyte Corporation

Drug Profile

Baricitinib - Eli Lilly and Company/Incyte Corporation

Alternative Names: INCB-028050; INCB-28050; LY-3009104; Olumiant

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Eli Lilly and Company; Incyte Corporation
  • Class Acetonitriles; Antipsoriatics; Antirheumatics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Uroprotectives
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase III Alopecia areata; Atopic dermatitis; Juvenile rheumatoid arthritis; Systemic lupus erythematosus
  • Phase II Giant cell arteritis; Primary biliary cirrhosis
  • Discontinued Diabetic nephropathies; Psoriasis; Psoriatic arthritis

Most Recent Events

  • 26 Sep 2019 Eli Lilly and Company completes a phase-II trial in in Primary biliary cirrhosis in Puerto Rico, USA, United Kingdom (PO) (NCT03742973) (EudraCT2018-003365-34 )
  • 17 Sep 2019 Eli Lilly plans the phase III JUVE-BRIGHT trial for Juvenile rheumatoid arthritis (In children, In adolescents, Treatment-experienced) or Uveitis (In children, In adolescents, Treatment-experienced) in Germany (PO) (EudraCT2019-000119-10) (NCT04088409)
  • 09 Sep 2019 Eli Lilly initiates enrolment in the phase III SLE-BRAVE-X trial for Systemic lupus erythematosus (In adults, In the elderly, Treatment-experienced) in the USA (PO) (NCT03843125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top